Govt calls up 2800 corporates to clear MSME dues (See TOG News')Inverted duty structure - A Case study (See 'TOG Insight')BrahMos Cruise Missile successfully test-fired from INS Chennai (See 'TOG News')TP - Assessment order passed by AO in respect of international transactions entered into by assessee & declaring them to be at arm's length without referring matter to TPO u/s 92CA, is erroneous & prejudicial to Revenue's interest - power of revision rightly exercised in such case: ITAT (See 'TOG Latest')I-T - Search assessment u/s 153A framed before Search operations are conducted or even before any evidence incriminating the assessee is found, are invalid: ITAT (See 'TOG Latest')Central Excise - The Tribunal is not vested with jurisdiction to adjudicate upon cases pertaining to rebate of duty - appeal not maintainable: CESTAT (See 'TOG Latest')Customs - Classification - Public Notice, even though issued by another Customs House, can validly be used as reference: CESTAT (See 'TOG Latest')Devitrification - scientists devise new way to dispose off nuclear waste (See 'TOG News')Scientists develop bio-inspired materials for energy sector (See 'TOG News')TP - An ITE service provider & KPO service provider cannot be compared for purposes of ALP determination - functional dissimilarity is sufficient grounds for exclusion of comparable: ITAT (See 'TOG Latest')I-T - Where refund of any amount u/s 244A(1) is due, assessee is entitled to simple interest and even single-day delay should be considered as part of the month for the purpose of computation of interest: ITAT (See 'TOG Latest')Central Excise - Grounds on which matter is decided by AA is entirely different from the case made out in SCN – matter remanded: CESTAT (See 'TOG Latest')Customs - Enhancement of declared value based on NIDB data is not permissible without first rejecting transaction value of imported goods: CESTAT (See 'TOG Latest')PFRDA crosses Rs 5 lakh crore AUM milestone (See 'TOG News')Railways issues policy on development of Goods-sheds through private investment (See 'TOG News')
Tax on Go
Budget 2015
Click the banner to download Documents


Minister expects Indian pharma to be among first one to develop vaccines
By TOG News Service
Sep 18, 2020

TOG NEWS SERVICE, NEW DELHI, SEPT 18, 2020: UNION Minister for Chemical  and Fertilizers, D V Sadananda Gowda, has lauded the contribution of Indian pharma industry during the testing time of COVID expressing confidence that Indian pharma industry will be among the first one to develop and supply low cost vaccines for this pandemic.

Mr Gowda was addressing a Webinar organised by Invest India Pharma Bureau and Department of pharmaceuticals on  #EIF2020 Medical Devices and Pharmaceutical Sector Edition - unravelling the investment potential, Gol initiatives, infrastructure & emerging opportunities in the sector through video conferencing yesterday evening.

Union Minister also stresse that Indian pharma and medical devices industry were able to rise to the occasion. He added, "It is matter of great pride for me and millions of Indians that from being a net importer, India has become second largest producer of PPE Kits in the world with daily production capacity surpassing more than 5 lakh per day.

Similarly in case of ventilators, within a very short span of time, indigenous production capacity has increased to 3 lakh per annum. In addition, India did not face any scarcity of medicines, prices of medicines remained stable throughout. This was achieved due to active cooperation among various Departments and agencies of the Central Government, State Governments and private sector, Mr Gowda said.

Stressing on the need of development of indigenous capacity in Medical devices Mr Gowda said, "it is very important as it has a crucial role to play in improving accessibility and affordability of healthcare especially with respect to availability of precision devices for screening and diagnosis, advanced surgical equipment needed for treatment, and devices for monitoring of health indicators, among others."

He further said under the leadership of  Prime Minister Mr Narendra Modi, Department of Pharmaceuticals has taken several measures to create enabling environment for development of domestic capacity in pharma and medical deivice sector and has decided to support the development of three bulk drug parks and four medical devices parks across the country in coordination with State Governments and private sector. The objective is to make India self reliant in production of 53 critical APIs or Key Starting Materials (KSMs), and in production of medical devices, for which India is crucially dependent upon imports.

Mr Gowda said that he is very much sure  that these  parks will be able to attract significant investment as well as latest technology.  Within a period of 2 -3 years, due to business friendly policies of Union Government under leadership of Mr Narendra Modi, pharma sector will become atmanirbhar, not only in sense of meeting domestic requirements but also for fulfilling global demand of low cost - high quality medicines and medical devices. It is expected that these schemes of Union Government for development of bulk drug & medical device park will attract cumulative investment of Rs 78000 crore and can generate about 2.5 lakh employment.